SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of some unusual options trading activity on Thursday. Stock traders acquired 8,459 put options on the company. This is an increase of approximately 208% compared to the typical volume of 2,742 put options.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Anson Funds Management LP acquired a new position in SELLAS Life Sciences Group in the third quarter valued at approximately $992,000. Geode Capital Management LLC boosted its stake in SELLAS Life Sciences Group by 17.1% during the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after acquiring an additional 88,183 shares in the last quarter. XTX Topco Ltd bought a new position in SELLAS Life Sciences Group during the third quarter worth $78,000. State Street Corp grew its holdings in SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after purchasing an additional 40,500 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in SELLAS Life Sciences Group in the second quarter valued at $39,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Trading Down 13.7 %

SLS stock traded down $0.16 during midday trading on Thursday, hitting $0.98. The stock had a trading volume of 24,724,938 shares, compared to its average volume of 3,326,094. The business has a fifty day moving average price of $1.05 and a two-hundred day moving average price of $1.16. SELLAS Life Sciences Group has a 1-year low of $0.50 and a 1-year high of $1.72. The firm has a market cap of $69.25 million, a P/E ratio of -1.44 and a beta of 2.41.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.